Angiotensin receptor blockers: Role in hypertension management, cardiovascular risk reduction, and nephropathy

Southern Medical Journal

Volumn 102, Issue 10 SUPPL. 1, 2009, Pages

  Basile, Jan ^a   Toth, Peter P ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiotensin II; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Cardioprotection; Diabetes mellitus; Heart failure; Hypertension; Nephropathy; Renoprotection

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; NITRENDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FOLLOW UP; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; PROGNOSIS; RENAL PROTECTION; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CONTROLLED CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; RISK FACTORS; TREATMENT OUTCOME;

EID: 74049140052     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181ba0d8a     Document Type: Review

References (51)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
2. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13:S9-S20.
3. Silverstein RL, Ram CV. Angiotensin-receptor blockers: Benefits beyond lowering blood pressure. Cleve Clin J Med 2005;72:825-832.
4. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001;37:1047-1052.
5. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003;16:123-126.
6. Joseph K, Kaplan AP. Formation of bradykinin: A major contributor to the innate inflammatory response. Adv Immunol 2005;86:159-208.
7. Tomaki M, Ichinose M, Miura M, et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 1996;51:199-201.
8. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3:311-317.
9. Contreras F, de la Parte MA, Cabrera J, et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003;10:401-408.
10. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
11. Hoit BD, Shao Y, Kinoshita A, et al. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995;95: 1519-1527.
12. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-195.
13. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 2000; 13(4 pt 1):418-426.
14. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008;10(suppl 1):27-32.
15. Plosker GL, Robinson DM. Amlodipine/Valsartan: Fixed-dose combination in hypertension. Drugs 2008;68:373-381.
16. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33. (Pubitemid 29355511)
17. Bohm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: Where do we stand now? Am J Cardiol 2007; 100(suppl 3A):38J- 44J.
18. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991;121(4 pt 1):1244-1263.
19. Wagenaar LJ, Voors AA, Buikema H, et al. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002;18:1331-1339.
20. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
21. Cohn JN. What is the role of angiotensin-receptor blockade in cardiovascular protection. Am Heart J 2006;152:859.e1- 859.e8.
22. Bradley RL, Cleveland KA, Cheatham B. The adipocyte as a secretory organ: Mechanisms of vesicle transport and secretory pathways. Recent Prog Horm Res 2001;56:329-358.
23. Nickenig G, Bäumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.
24. Yasunari K, Maeda K, Nakamura M, et al. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents 2005;3:61-67.
25. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
26. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.
27. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008;372:1174-1183.
28. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-2031.
29. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of newonset type 2 diabetes. Diabetes Care 2005;28:2261-2266.
30. Bakris G, Stockert J, Molitch M, et al; STAR Investigators. Risk factor assessment for new onset diabetes: Literature review. Diabetes Obes Metab 2009;11:177-187.
31. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-826.
32. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox. Circulation 2006;114:838-854.
33. Ripley TL, Harrison D. The power to TRANSCEND. Lancet 2008;372: 1128-1130.
34. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
35. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
36. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARMAdded trial. Lancet 2003;362:767-771. (Pubitemid 37093916)
37. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772-776. (Pubitemid 37093917)
38. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
39. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
40. White WB. Update on the drug treatment of hypertension in patients with cardiovascular disease. Am J Med 2005;118:695-705.
41. Weber MA. New opportunities in cardiovascular patient management: A survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007; 100:45J-52J.
42. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001;161:1492-1499.
43. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
44. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961.
45. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
46. Parving HH, Lehnert H, Bröchner-Mortensen J, et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878. (Pubitemid 34940826)
47. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressureindependent effect. Circulation 2002;106:672-678.
48. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
49. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-869. (Pubitemid 34940825)
50. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
51. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 2008;358:2503-2505.